Recommendation ID

Allogeneic stem cell transplantation:- What is the effectiveness of combined autologous–allogeneic stem cell transplantation compared with autologous stem cell transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first relapse?

Any explanatory notes
(if applicable)

Why this is important:- There are conflicting data from a small number of studies on long-term survival following auto/allo stem cell transplantation compared with autologous stem cell transplantation. These studies were performed before thalidomide, bortezomib and lenalidomide were used as myeloma treatments.
These drugs produce better responses and also have the capacity to affect immunological responses after the transplant. Research is needed to see if there is a role for auto/allo stem cell transplant in the ongoing treatment of myeloma. Outcomes of interest are progression-free survival, overall survival, transplant-related mortality, quality of life, early and late toxicity including graft-versus-host-disease (GvHD) and resource use. This research should be included as an option in appropriate mainstream clinical trials for myeloma.

Source guidance details

Comes from guidance
Myeloma: diagnosis and management
Date issued
February 2016

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 29/02/2016